Publications by authors named "J Rustige"
Atrial fibrillation (AF) is a common clinically significant cardiac arrhythmia. This phase 3 randomized, double-blind, placebo-controlled trial assessed the efficacy and safety of vernakalant hydrochloride for the pharmacological conversion of AF to sinus rhythm in patients with recent-onset (>3 hours to ≤7 days) symptomatic AF from the Asia-Pacific region. Patients received an infusion of vernakalant (3 mg/kg) or placebo for 10 minutes.
View Article and Find Full Text PDFA roadmap to improve the quality of atrial fibrillation management: proceedings from the fifth Atrial Fibrillation Network/European Heart Rhythm Association consensus conference.
Europace
January 2016
Article Synopsis
- Atrial fibrillation (AF) affects at least 30 million people globally and is associated with significant health risks like strokes, heart failure, and high mortality rates, even with existing treatments.
- There is a critical need to improve preventive measures and identify treatable causes of AF, as many cases remain undiagnosed or poorly managed.
- The fifth Atrial Fibrillation Network conference focused on enhancing AF care through collaboration, patient-centered approaches, structured management, quality improvement, and personalized treatment plans, alongside outlining key research priorities for AF.
In autologous and allogeneic hematopoietic SCT (HSCT) neutropenia may be associated with severe infection. Immunodeficiency associated with GVHD and its treatment in allogeneic HSCT is also a risk for severe infection. In both periods, patients may develop severe sepsis with organ failure.
View Article and Find Full Text PDF